A SUR1/Kir6.2 inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Mitiglinide (calcium salt)

Item No. 30693

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(αS,3aR,7aS)-octahydro-γ-oxo-α-(phenylmethyl)-2H-isoindole-2-butanoic acid, hemicalcium salt
CAS Number
145525-41-3
Synonyms
  • KAD-1229
  • S21403
Molecular Formula
C19H24NO3 • 1/2Ca
Formula Weight
334.4
Purity
≥98% (mixture of isomers)
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
Chloroform: slightly solubleDMF: slightly solubleDMSO: slightly solubleMethanol: slightly soluble
λmax
239 nm
SMILES
O=C(C[C@H](CC1=CC=CC=C1)C([O-])=O)N2C[C@@]3([H])CCCC[C@@]3([H])C2.O=C(C[C@H](CC4=CC=CC=C4)C([O-])=O)N5C[C@@]6([H])CCCC[C@@]6([H])C5.[Ca+2]
InChi Code
InChI=1S/2C19H25NO3.Ca/c2*21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14;/h2*1-3,6-7,15-17H,4-5,8-13H2,(H,22,23);/q;;+2/p-2/t2*15-,16+,17-;/m00./s1
InChi Key
PMRVFZXOCRHXFE-FMEJWYFOSA-L
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    50 mg

    $95

    Add

    100 mg

    $149

    Add

    250 mg

    $326

    Add

    500 mg

    $510

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Mitiglinide is an inhibitor of sulfonylurea receptor 1 (SUR1) linked to ATP-sensitive potassium channel Kir6.2 (IC50 = 4 nM).1 It is selective for SUR1/Kir6.2 over SUR2A/Kir6.2 and SUR2B/Kir6.2 channels (IC50s = 3 and 5 µM, respectively). Mitiglinide induces insulin release in HIT-T15 insulinoma cells and isolated mouse pancreatic islets when used at a concentration of 100 µM.2 Oral administration of mitiglinide (1, 3, and 10 mg/kg) increases postprandial plasma insulin levels and inhibits postprandial increases in plasma glucose levels in a rat model of diabetes induced by streptozotocin (STZ; Item No. 13104).3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Reimann, F., Proks, P., and Ashcroft, F.M. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br. J. Pharmacol. 132(7), 1542-1548 (2001).

    2. Ohnota, H., Koizumi, T., Tsutsumi, N., et al. Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: Comparison of effects between KAD-1229 and gliclazide. J. Pharmacol. Exp. Ther. 269(2), 489-495 (1994).

    3. Ohnota, H., Kitamura, T., Kinukawa, M., et al. A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. Jpn. J. Pharmacol. 71(4), 315-323 (1996).